Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin97.8%-0.1pp97.8%+0.4pp97.4%+0.4pp97%+0.1pp96.9%-0.4pp
Operating margin-43.1%-82.1pp39%+26.3pp12.7%+3.0pp9.7%+3.1pp6.6%+7.2pp
Net margin-51.7%-81.9pp30.2%+31.6pp-1.5%+4.9pp-6.4%+4.2pp-10.6%+9.1pp
Efficiency
Asset turnover1.9×+0.1×1.7×+0.5×1.3×+0.1×1.2×+0.1×1.1×+0.2×
Liquidity
Current ratio1.9×-0.2×2.1×+0.2×1.9×-0.4×2.2×-0.7×2.9×+0.3×
Per Share
Book value per share-$2.29-319%-$0.55+69.1%-$1.76+8.0%-$1.92+8.7%-$2.10+8.8%
Valuation
Market capitalization$2.39B+45.3%$1.64B+3.2%$1.59B-23.3%$2.08B+32.6%$1.57B+0.6%
Price / sales2.7×+0.8×1.9×-0.8×2.7×-1.1×3.7×+0.6×3.1×-0.3×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are BioCryst Pharmaceuticals's profit margins?
BioCryst Pharmaceuticals (BCRX) runs a 97.8% gross margin and a -43.1% operating margin, with a -51.7% net margin.
Where do BioCryst Pharmaceuticals's ratios come from?
Every ratio is computed from BioCryst Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.